首页> 外文期刊>Therapeutic Drug Monitoring >Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.
【24h】

Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.

机译:依普利农和地高辛之间的干扰在荧光偏振免疫测定,微粒酶免疫测定和亲和柱介导的免疫测定中。

获取原文
获取原文并翻译 | 示例
       

摘要

Digitalis-like immunoreactive substances have crossreactivity with antidigoxin antibodies and the interference between digoxin and spironolactone/canrenone has been reported. The structure of eplerenone is similar to that of spironolactone/canrenone. Therefore, we hypothesized that eplerenone might also interfere with the measurement of digoxin by immunoassay. We performed three types of assays (fluorescence polarization immunoassay [FPIA], microparticle enzyme immunoassay [MEIA], and affinity column-mediated immunoassay [ACMIA]) to determine crossreactions between eplerenone and antidigoxin antibodies. Furthermore, we used FPIA, MEIA, and ACMIA to measure the apparent digoxin concentration in mixed solutions of eplerenone (1-100 mug/mL) and digoxin (1-3 ng/mL). In the crossreaction tests, eplerenone was detected as digoxin by FPIA and ACMIA. By FPIA, a known concentration of 1 mug/mL of eplerenone was measured as 0.33 +/- 0.11 ng/mL of digoxin (crossreaction rate, 0.03%). By ACMIA, a known concentration of 10 mug/mL of eplerenone was measured as 0.13 +/- 0.05 ng/mL of digoxin (crossreaction rate, 0.001%). No crossreaction between eplerenone and digoxin was determined by MEIA. In the interference of eplerenone coadministered with digoxin, the apparent concentration of digoxin was increased in FPIA, but decreased in MEIA and ACMIA. The results suggest that eplerenone crossreacts with antidigoxin antibodies in FPIA, MEIA, and ACMIA, but that the interference of eplerenone might be smaller than that of spironolactone/canrenone.
机译:洋地黄样免疫反应物质与抗地高辛抗体具有交叉反应性,并且已报道了地高辛与螺内酯/睾丸内酮之间的干扰。依匹乐酮的结构类似于螺内酯/佳耐乐酮。因此,我们假设依普利农也可能干扰免疫测定法对地高辛的测定。我们进行了三种类型的测定(荧光偏振免疫测定[FPIA],微粒酶免疫测定[MEIA]和亲和柱介导的免疫测定[ACMIA]),以确定依普利农和抗地高辛抗体之间的交叉反应。此外,我们使用FPIA,MEIA和ACMIA来测量依普利农(1-100杯/毫升)和地高辛(1-3 ng / mL)混合溶液中的地高辛表观浓度。在交叉反应测试中,FPIA和ACMIA将依普利农检测为地高辛。通过FPIA,已知的依普利农1杯/毫升的已知浓度为地高辛0.33 +/- 0.11 ng / mL(交叉反应率,0.03%)。通过ACMIA,已知的10杯/毫升依匹乐酮的已知浓度为地高辛0.13 +/- 0.05 ng / mL(交叉反应率,0.001%)。 MEIA未确定依普利农与地高辛之间的交叉反应。在依匹乐酮与地高辛合用的干扰中,地高辛的表观浓度在FPIA中升高,但在MEIA和ACMIA中降低。结果表明,依普利农在FPIA,MEIA和ACMIA中与抗地高辛抗体发生交叉反应,但依普利农的干扰可能小于螺内酯/佳耐乐酮。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号